drugset / Trial / NCT01709656
A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis
RandomizedParallel-groupOpen-label
Summary
The investigators will recruit active ankylosing spondylitis patients for injection treatment of Human Mesenchymal Stem Cells (a prospective, open-label, masculine medicine controlled(NSAIDs), clinical trial), and collect their Peripheral Blood Lymphocyte (PBMCs) and sera before and after the treatment of 24 weeks to test the gene expression profiles and study related pathogenesis of AS
Timeline
- Start
- 2012-03
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MSC | Cell therapy | 10000 cells/kg | Intravenous |
| Subject | MSC | Cell therapy | 1e+06 cells/kg | Intravenous |
| Background | Celecoxib | Other / unclassified | 0.2 g | Oral |